All news

argenx to buy Unnatural Products for up to

BioPharm International · · AI-summarised by FinFlash

Belgian biotech argenx agreed to acquire Santa Cruz-based Unnatural Products, a macrocyclic peptide discovery company, for up to about

So What?

The bolt-on adds an oral peptide platform to argenx's immunology pipeline with limited balance sheet strain. Watch for disclosure of specific programs and targets.

Read original source

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.